To evaluate the efficacy of savolitinib in a patient with non-small cell lung cancer (NSCLC) harboring METex14 skipping mutations and presenting with brain and leptomeningeal metastases, emphasizing the significance of this mutation in treatment outcomes.
Key Findings:
The patient showed significant clinical improvement with savolitinib, achieving an intracranial partial response, with specific metrics to be included.
NGS-based detection of ctDNA in CSF is effective for identifying actionable mutations in CNS metastases, highlighting its clinical utility.
Savolitinib demonstrated a manageable safety profile with mild adverse effects, warranting further investigation.
Interpretation:
Savolitinib may be a promising treatment option for NSCLC patients with CNS metastases harboring METex14 mutations, highlighting the importance of molecular profiling in treatment decisions and future research directions.
Limitations:
The study is based on a single case, limiting generalizability and potential biases.
Long-term outcomes and broader efficacy in larger populations remain to be established, necessitating further studies.
Conclusion:
Savolitinib shows potential as a novel therapeutic strategy for NSCLC patients with brain and leptomeningeal metastases, warranting further investigation to validate these findings.
